Active ownership: a time-consuming burden, or a useful exercise? To find out how companies look at this, Robeco talked to Alexander Klauser, Head of Sustainability Communications at Swiss healthcare company Roche.
Robeco’s active ownership team recently concluded an engagement on ESG risks and opportunities in the biopharmaceutical industry. Roche was one of the eleven companies under engagement. Robeco talked to Alexander Klauser about five material topics, i.e. innovation management, product quality & safety management, business ethics, clinical trial transparency and access to medicine.
“Medicines account for only a small part of health costs (16%, WHO 2017). When we do our job right – extend patients’ lives – we help to reduce the other
“In our pricing, we strive for the right balance between ensuring people have access to the medicines they need, while investing in future breakthroughs. We have a very high threshold for new medicines. It’s no use developing a subpar product which will not deliver additional benefit for patients. Our business is a lot more riskier than ten years ago, and as a company we need to earn a premium to take this risk. After all, we might fail in certain medicines and when this happens, we need to have the financial power to carry on. We have open discussions about this with our stakeholders.
“We know that quality and safety – not harming patients – are our license to operate. We are among the most highly regulated industries. We appreciate that you flagged this topic, as it confirmed the high importance we attach to it. In our talks, you highlighted very important issues, such as product recalls. You made us more aware that any warning letter or recall will result in Roche being punished by the market.”
“We can exclude systematic, but we cannot exclude individual violations. However, we guarantee that we do not turn a blind eye if things go wrong. There is zero tolerance, and any wrongdoing will be sanctioned. To enable our company to operate with high standards, we transformed from ‘formal compliance’ to ‘business-integrated sustainable compliance’. For example, we do not simply record payments we make to doctors and hospitals, but our line management critically examines the purpose of the payments. Why are we making these payments? What is their impact on society? Being transparent about this creates trust.”
“We share information on all Roche-sponsored safety and efficacy studies, also when the outcome is negative. This helps physicians, patients and healthcare providers to make informed treatment decisions. It can also enable researchers to build on our research and that of others, in the hope of advancing scientific progress. We are making progress but acknowledge that our work is far from complete. We are committed to working with industry partners and others in the scientific community to advance opportunities for data sharing.
“The engagement with you confirmed that it doesn’t help healthcare if companies are not transparent about their clinical trials. We have to address this as an industry.”
“Access to our products is a critical part of our strategy. Also from a business perspective, it’s important to know how we can get the medicine and tests to people who really need it. Many patients lack access to the most essential health services. Often, the problem lies not only in the price of medicines but also in the system - for example, if the medical infrastructure or mandatory health insurance is lacking. The only way to achieve enduring solutions is working together in each country to ensure that all factors such as awareness, diagnosis, healthcare capacity and funding are addressed. We have access plans for 75 countries.
“In addition, access to medicine needs to be tackled by multiple stakeholders. Certain governments, for example, allocate more money to military purposes than to medicine. They should reevaluate their priorities and look beyond the next elections. In countries with little money to spend, we work with insurance companies to find financial solutions and make sure people get the medicine they need.
“In our discussions, you made us aware of the importance of transparency. We now make our internal access goals publicly available.
“You really pointed our attention to questions that you as investors have. This makes us more aware of what you need. We now have a more integrated way of talking about our business, addressing both financial and non-financial issues. All our employees are subject to impact analysis in their performance review. This is in line with your focus on impact investing, as you explained during our conversations. Also, the questions we get from investors such as Robeco form an important input for our discussions within the company.
“What was particularly insightful was your input on the impact of our business on the UN Sustainable Development Goals. We have a strategy that aims to make a ‘net positive impact on society’. Our honest discussions about the UN SDGs helped our internal processes. In short, our work with you continues to support Roche in staying ahead of the curve on sustainability.
The contents of this document have not been reviewed by the Securities and Futures Commission ("SFC") in Hong Kong. If you are in any doubt about any of the contents of this document, you should obtain independent professional advice. This document has been distributed by Robeco Hong Kong Limited (‘Robeco’). Robeco is regulated by the SFC in Hong Kong.
This document has been prepared on a confidential basis solely for the recipient and is for information purposes only. Any reproduction or distribution of this documentation, in whole or in part, or the disclosure of its contents, without the prior written consent of Robeco, is prohibited. By accepting this documentation, the recipient agrees to the foregoing
This document is intended to provide the reader with information on Robeco’s specific capabilities, but does not constitute a recommendation to buy or sell certain securities or investment products. Investment decisions should only be based on the relevant prospectus and on thorough financial, fiscal and legal advice. Please refer to the relevant offering documents for details including the risk factors before making any investment decisions.
The contents of this document are based upon sources of information believed to be reliable. This document is not intended for distribution to or use by any person or entity in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.
Investment Involves risks. Historical returns are provided for illustrative purposes only and do not necessarily reflect Robeco’s expectations for the future. The value of your investments may fluctuate. Past performance is no indication of current or future performance.
Please read this information carefully.
This website is prepared and issued by Robeco Hong Kong Limited ("Robeco"), which is a corporation licensed by the Securities and Futures Commission in Hong Kong to engage in Type 1 (dealing in securities); Type 4 (advising in securities) and Type 9 (asset management) regulated activities. The Company does not hold client assets and is subject to the licensing condition that it shall seek the SFC’s prior approval before extending services at retail level. This website has not been reviewed by the Securities and Futures Commission or any regulatory authority in Hong Kong.
2. Important risk disclosures
2. Important risk disclosures Robeco Capital Growth Funds (“the Funds”) are distinguished by their respective specific investment policies or any other specific features. Please read carefully for the risks of the Funds:
3. Local legal and sales restrictions
The information contained in the Website is being provided for information purposes.
Neither information nor any opinion expressed on the Website constitutes a solicitation, an offer or a recommendation to buy, sell or dispose of any investment, to engage in any other transaction or to provide any investment advice or service. The information contained in the Website does not constitute investment advice or a recommendation and was prepared without regard to the specific objectives, financial situation or needs of any particular person who may receive it. An investment in a Robeco product should only be made after reading the related legal documents such as management regulations, prospectuses, most recent annual and semi-annual reports, which can be all be obtained free of charge at www.robeco.com/hk/en and at the Robeco Hong Kong office.
4. Use of the Website
The information is based on certain assumptions, information and conditions applicable at a certain time and may be subject to change at any time without notice. Robeco aims to provide accurate, complete and up-to-date information, obtained from sources of information believed to be reliable. Persons accessing the Website are responsible for their choice and use of the information.
5. Investment performance
No assurance can be given that the investment objective of any investment products will be achieved. No representation or promise as to the performance of any investment products or the return on an investment is made. The value of your investments may fluctuate. The value of the assets of Robeco investment products may also fluctuate as a result of the investment policy and/or the developments on the financial markets. Results obtained in the past are no guarantee for the future. Past performance, projection, or forecast included in this Website should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied, is made regarding future performance. Fund performance figures are based on the month-end trading prices and are calculated on a total return basis with dividends reinvested. Return figures versus the benchmark show the investment management result before management and/or performance fees; the fund returns are with dividends reinvested and based on net asset values with prices and exchange rates of the valuation moment of the benchmark.
Investments involve risks. Past performance is not a guide to future performance. Potential investors should read the terms and conditions contained in the relevant offering documents and in particular the investment policies and the risk factors before any investment decision is made. Investors should ensure they fully understand the risks associated with the fund and should also consider their own investment objective and risk tolerance level. Investors are reminded that the value and income (if any) from shares of the fund may be volatile and could change substantially within a short period of time, and investors may not get back the amount they have invested in the fund. If in doubt, please seek independent financial and professional advice.
6. Third party websites
This website includes material from third parties or links to websites maintained by third parties some of which is supplied by companies that are not affiliated to Robeco. Following links to any other off-site pages or websites of third parties shall be at the own risk of the person following such link. Robeco has not reviewed any of the websites linked to or referred to by the Website and does not endorse or accept any responsibility for their content nor the products, services or other items offered through them. Robeco shall have no liability for any losses or damages arising from the use of or reliance on the information contained on websites of third parties, including, without limitation, any loss of profit or any other direct or indirect damage. Third party off-site pages or websites are provided for informational purposes only.
7. Limitation of liability
Robeco as well as (possible) other suppliers of information to the Website accept no responsibility for the contents of the Website or the information or recommendations contained herein, which moreover may be changed without notice.
Robeco assumes no responsibility for ensuring, and makes no warranty, that the functioning of the Website will be uninterrupted or error-free. Robeco assumes no responsibility for the consequences of e-mail messages regarding a Robeco (transaction) service, which either cannot be received or sent, are damaged, received or sent incorrectly, or not received or sent on time.
Neither will Robeco be liable for any loss or damage that may result from access to and use of the Website.
8. Intellectual property
All copyrights, patents, intellectual and other property, and licenses regarding the information on the Website are held and obtained by Robeco. These rights will not be passed to persons accessing this information.
10. Applicable law
The Website shall be governed by and construed in accordance with the laws of Hong Kong. All disputes arising out of or in connection with the Website shall be submitted to the exclusive jurisdiction of the courts of Hong Kong.